Antigenic fingerprinting of RSV-A infected hematopoietic cell transplant recipients reveals importance of mucosal anti-RSV-G antibodies in control of RSV infection in humans.
Respiratory syncytial virus (RSV) infection causes significant morbidity in hematopoietic cell transplants (HCT) patients. However, antibody response that correlate with recovery from RSV disease are not fully understood. In this study, antibody repertoire in paired serum and nasal wash samples from acutely RSV-A infected HCT patients who recovered early (<14 days RSV shedding) were compared with late-recovered patients (>14 days shedding) using gene fragment phage display libraries (GFPDL) and surface plasmon resonance (SPR). Anti-F serum response were similar between these two groups for antibody repertoires, neutralization titers, anti-F binding antibodies (pre-fusion and post-fusion proteins), antibody avidity and binding to specific antigenic sites. In contrast, nasal washes from early-recovered individuals demonstrated higher binding to F peptide containing p27. While the serum RSV-G antibody repertoires in the two groups were similar, the strongest difference between early-recovered and late-recovered patients was observed in the titers of nasal wash antibodies, especially binding to the central conserved domain (CCD). Most importantly, a significantly higher antibody affinity to RSV-G was observed in nasal washes from early-recovered individuals compared with late-recovered HCT patients. These findings highlight the importance of mucosal antibodies in resolution of RSV-A infection in the upper respiratory tract.